JP2021530244A5 - - Google Patents

Info

Publication number
JP2021530244A5
JP2021530244A5 JP2021503901A JP2021503901A JP2021530244A5 JP 2021530244 A5 JP2021530244 A5 JP 2021530244A5 JP 2021503901 A JP2021503901 A JP 2021503901A JP 2021503901 A JP2021503901 A JP 2021503901A JP 2021530244 A5 JP2021530244 A5 JP 2021530244A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
amino acid
Prior art date
Application number
JP2021503901A
Other languages
English (en)
Japanese (ja)
Other versions
JP7525471B2 (ja
JPWO2020023644A5 (https=
JP2021530244A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043254 external-priority patent/WO2020023644A2/en
Publication of JP2021530244A publication Critical patent/JP2021530244A/ja
Publication of JP2021530244A5 publication Critical patent/JP2021530244A5/ja
Publication of JPWO2020023644A5 publication Critical patent/JPWO2020023644A5/ja
Priority to JP2024053871A priority Critical patent/JP2024105229A/ja
Application granted granted Critical
Publication of JP7525471B2 publication Critical patent/JP7525471B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503901A 2018-07-24 2019-07-24 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体 Active JP7525471B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024053871A JP2024105229A (ja) 2018-07-24 2024-03-28 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702762P 2018-07-24 2018-07-24
US62/702,762 2018-07-24
PCT/US2019/043254 WO2020023644A2 (en) 2018-07-24 2019-07-24 Antibody directed against s. aureus clumping factor a (clfa)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024053871A Division JP2024105229A (ja) 2018-07-24 2024-03-28 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体

Publications (4)

Publication Number Publication Date
JP2021530244A JP2021530244A (ja) 2021-11-11
JP2021530244A5 true JP2021530244A5 (https=) 2022-08-01
JPWO2020023644A5 JPWO2020023644A5 (https=) 2022-08-01
JP7525471B2 JP7525471B2 (ja) 2024-07-30

Family

ID=67539640

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503901A Active JP7525471B2 (ja) 2018-07-24 2019-07-24 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体
JP2024053871A Pending JP2024105229A (ja) 2018-07-24 2024-03-28 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024053871A Pending JP2024105229A (ja) 2018-07-24 2024-03-28 S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体

Country Status (10)

Country Link
US (3) US11155606B2 (https=)
EP (1) EP3840838A2 (https=)
JP (2) JP7525471B2 (https=)
CN (2) CN112672788B (https=)
AU (1) AU2019309366B2 (https=)
BR (1) BR112021001214A2 (https=)
CA (1) CA3107463A1 (https=)
MX (1) MX2021000889A (https=)
TW (1) TWI902669B (https=)
WO (1) WO2020023644A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
DE102018115012A1 (de) 2018-06-21 2019-12-24 Carl Zeiss Microscopy Gmbh Teilchenstrahlsystem
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
TWI743626B (zh) 2019-01-24 2021-10-21 德商卡爾蔡司多重掃描電子顯微鏡有限公司 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品
DE102019008249B3 (de) 2019-11-27 2020-11-19 Carl Zeiss Multisem Gmbh Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt
AU2024269156A1 (en) * 2023-05-09 2026-01-08 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1377314E (pt) * 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
EP1479695B1 (en) 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
CN1324049C (zh) 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体
US20050226878A1 (en) 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CN102171247A (zh) 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-α拮抗剂多靶点结合蛋白
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US8609102B2 (en) 2009-05-18 2013-12-17 Julius-Maximilians-Universitat Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of ISAA or ISAB
RU2677140C1 (ru) 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
EP3470526A3 (en) 2011-02-08 2019-07-17 Medimmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
MX357938B (es) 2011-06-19 2018-07-31 Univ New York Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.
RU2654596C2 (ru) 2012-03-19 2018-05-21 Текнифар-Индустриа Текника Фармасеутика С.А. Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US9845348B2 (en) 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
EP3057989A1 (en) 2013-10-17 2016-08-24 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody sequences
MX2016007533A (es) 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
MX2016007212A (es) 2013-12-19 2016-09-07 Arsanis Biosciences Gmbh Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
MX2017012775A (es) 2015-04-17 2019-04-29 Arsanis Biosciences Gmbh Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合

Similar Documents

Publication Publication Date Title
JP2021530244A5 (https=)
JP2021534762A5 (https=)
JP2024105229A5 (https=)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP7189211B2 (ja) 血清中のタンパク質の半減期を増加させるための組成物及び方法
JP2020518248A5 (https=)
JP2017523984A5 (https=)
JP2024001073A5 (https=)
JP7830445B2 (ja) インターロイキン1アルファに特異的な真のヒト抗体
US10640576B2 (en) Cell engaging binding molecules
FI4200018T3 (fi) Anti-par-2-vasta-aineet ja niiden käyttömenetelmät
CN106243223B (zh) 抗人pdl1抗体及其用途
JPWO2022111425A5 (https=)
JPWO2020023644A5 (https=)
JP7821161B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
JP2021514369A5 (https=)
JP2026506070A (ja) 抗cntn4抗体及びその使用
JPWO2020076790A5 (https=)
JPWO2022068854A5 (https=)
CN117677635A (zh) 新颖pd-1结合域
JPWO2021207072A5 (https=)
JP7821159B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
JPWO2021119531A5 (https=)
RU2021104263A (ru) АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus